Advanced search
Publication Cover
Leukemia & Lymphoma Volume 63, 2022 - Issue 14
Submit an article Journal homepage
183
Views
0
CrossRef citations to date
0
Altmetric
Original Articles

Infectious complications and long-term outcomes in patients with diffuse large B-Cell lymphoma and diabetes mellitus

Oren Pasvolskya Institute of Hematology, Davidoff Center, Rabin Medical Center, Beilinson Hospital, Petach-Tikva, Israel;b Sackler School of Medicine, Tel Aviv University, Tel Aviv, IsraelCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-9193-0059
ORCID Icon,
Tamar Bergera Institute of Hematology, Davidoff Center, Rabin Medical Center, Beilinson Hospital, Petach-Tikva, Israel;b Sackler School of Medicine, Tel Aviv University, Tel Aviv, IsraelORCID Iconhttps://orcid.org/0000-0001-5547-6936
ORCID Icon,
Karyn Revital Geigera Institute of Hematology, Davidoff Center, Rabin Medical Center, Beilinson Hospital, Petach-Tikva, Israel;b Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
,
Amit Akirovb Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel;c Institute of Endocrinology, Beilinson Hospital, Petach-Tikva, Israel
,
Elias Bsharab Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
,
Pia Raanania Institute of Hematology, Davidoff Center, Rabin Medical Center, Beilinson Hospital, Petach-Tikva, Israel;b Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
,
Anat Gafter-Gvilia Institute of Hematology, Davidoff Center, Rabin Medical Center, Beilinson Hospital, Petach-Tikva, Israel;b Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel;d Medicine A, Rabin Medical Center, Beilinson Hospital, Petach- Tikva, Israel
,
Tzippy Shochate Bio-Statistical Unit, Rabin Medical Center, Beilinson Campus, Petah Tikva, Israel
,
Uri Rozovskia Institute of Hematology, Davidoff Center, Rabin Medical Center, Beilinson Hospital, Petach-Tikva, Israel;b Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
&
Ronit Guriona Institute of Hematology, Davidoff Center, Rabin Medical Center, Beilinson Hospital, Petach-Tikva, Israel;b Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
 show all
Pages 3378-3384 | Received 15 Oct 2021, Accepted 19 Aug 2022, Published online: 06 Sep 2022

References

  • Armitage JO. How I treat patients with diffuse large B-cell lymphoma. Blood. 2007;110(1):29–36.
  • Liu Y, Barta SK. Diffuse large B-cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment. Am J Hematol. 2019;94(5):604–616.
  • Gea-Banacloche JC. Rituximab-associated infections. Semin Hematol. 2010;47(2):187–198.
  • Pettengell R, Bosly A, Szucs TD, et al. Multivariate analysis of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma: data from the INC-EU prospective observational European neutropenia study. Br J Haematol. 2009;144(5):677–685.
  • Deresinski S. Infections in the diabetic patient: strategies for the clinician. Infect Dis Rep. 1995;1:1–12.
  • Geerlings SE, Hoepelman AI. Immune dysfunction in patients with diabetes mellitus (DM). FEMS Immunol Med Microbiol. 1999;26(3–4):259–265.
  • Taplitz RA, Kennedy EB, Bow EJ, et al. Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA clinical practice guideline update. J Clin Oncol. 2018;36(30):3043–3054.
  • Hosmer W, Malin J, Wong M. Development and validation of a prediction model for the risk of developing febrile neutropenia in the first cycle of chemotherapy among elderly patients with breast, lung, colorectal, and prostate cancer. Support Care Cancer. 2011;19(3):333–341.
  • Smith TJ, Bohlke K, Lyman GH, et al. Recommendations for the use of WBC growth factors: American society of clinical oncology clinical practice guideline update. J Clin Oncol. 2015;33(28):3199–3212.
  • Potter M, Newport E, Morten KJ. The warburg effect: 80 years on. Biochem Soc Trans. 2016;44(5):1499–1505.
  • Chao C, Page JH. Type 2 diabetes mellitus and risk of non-Hodgkin lymphoma: a systematic review and meta-analysis. Am J Epidemiol. 2008;168(5):471–480.
  • Wang XJ, Lopez SE, Chan A. Economic burden of chemotherapy-induced febrile neutropenia in patients with lymphoma: a systematic review. Crit Rev Oncol Hematol. 2015;94(2):201–212.
  • Bosly A, Bron D, Van Hoof A, et al. Achievement of optimal average relative dose intensity and correlation with survival in diffuse large B-cell lymphoma patients treated with CHOP. Ann Hematol. 2008;87(4):277–283.
  • Alba-Loureiro TC, Munhoz CD, Martins JO, et al. Neutrophil function and metabolism in individuals with diabetes mellitus. Braz J Med Biol Res. 2007;40(8):1037–1044.
  • Aapro MS, Bohlius J, Cameron DA, et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer. 2011;47(1):8–32.
  • Lyman GH, Lyman CH, Agboola O. Risk models for predicting chemotherapy-induced neutropenia. Oncologist. 2005;10(6):427–437.
  • Klastersky J, Paesmans M, Rubenstein EB, et al. The multinational association for supportive care in cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol. 2000;18(16):3038–3051.
  • Carmona-Bayonas A, Gomez J, Gonzalez-Billalabeitia E, et al. Prognostic evaluation of febrile neutropenia in apparently stable adult cancer patients. Br J Cancer. 2011;105(5):612–617.
  • Soysal DE, Karakus V, Seren AR, et al. Evaluation of transient hyperglycemia in non-diabetic patients with febrile neutropenia. Eur J Intern Med. 2012;23(4):342–346.
  • GH, Lyman MK, J, Crawford DA, Wolff, et al. Prospective validation of a risk model for first cycle neutropenic complications in patients receiving cancer chemotherapy. J Clin Oncol. 2006;24(18_suppl):8561–8561.
  • Drozd-Sokolowska J, Zaucha JM, Biecek P, et al. Type 2 diabetes mellitus compromises the survival of diffuse large B-cell lymphoma patients treated with (R)-CHOP – the PLRG report. Sci Rep. 2020;10(1):3517.
  • Koo YX, Tan DS, Tan IB, et al. Effect of concomitant statin, metformin, or aspirin on rituximab treatment for diffuse large B-cell lymphoma. Leuk Lymphoma. 2011;52(8):1509–1516.
  • Wang Y, Maurer MJ, Larson MC, et al. Impact of metformin use on the outcomes of newly diagnosed diffuse large B-cell lymphoma and follicular lymphoma. Br J Haematol. 2019;186(6):820–828.
  • Alkhatib Y, Abdel Rahman Z, Kuriakose P. Clinical impact of metformin in diabetic diffuse large B-cell lymphoma patients: a case-control study. Leuk Lymphoma. 2017;58(5):1130–1134.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.